PRTA
Prothena Corporation plc
Halal Rating :
Last Price
$13.73
Last updated:
Market Cap
-
7D Change
4.57%
1 Year Change
-59.7%
Company Overview
Industries
Exchange
Next Earnings Date
Prothena Corporation plc is a late-stage clinical biotechnology company focused on developing novel therapies for rare peripheral amyloid and neurodegenerative diseases. The company's pipeline includes treatments for AL amyloidosis, ATTR amyloidosis, Alzheimer's disease, and Parkinson's disease.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $970000.0 | $60.74m | - | $-6743000.0 | 0.00% | 11.10% |
| June 30, 2024 | $132.01m | $67.12m | - | $-6521000.0 | 0.00% | 9.72% |
| March 31, 2024 | $50000.0 | $74.41m | - | $-7165000.0 | 0.00% | 9.63% |
Company Impact
Help us evaluate Prothena Corporation plc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.